1,269 results on '"Verkade, Henkjan"'
Search Results
2. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
3. Longitudinal relationship between albuminuria in infancy and childhood
4. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
5. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review
6. Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol
7. Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia.
8. EASL-ERN position paper on liver involvement in patients with Fontan-type circulation
9. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
10. Odevixibat Treatment Induces Biliary Bile Acid Secretion in Responsive Patients With Bile Salt Export Pump Deficiency
11. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency
12. WED-166 Efficacy and safety of odevixibat in a subgroup of adult patients with progressive familial intrahepatic cholestasis in the PEDFIC 2 study
13. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial
14. High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia
15. Mice with a deficiency in Peroxisomal Membrane Protein 4 (PXMP4) display mild changes in hepatic lipid metabolism
16. Parental wellbeing after diagnosing a child with biliary atresia: A prospective cohort study
17. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
18. The spectrum of Progressive Familial Intrahepatic Cholestasis diseases: Update on pathophysiology and emerging treatments
19. Donor genetic variants as risk factors for thrombosis after liver transplantation: A genome-wide association study
20. Lifelines NEXT : a prospective birth cohort adding the next generation to the three-generation Lifelines cohort study
21. Defining the natural history of rare genetic liver diseases: Lessons learned from the NAPPED initiative
22. 3.9 Nutritional Management in Cholestatic Liver Disease
23. The role of the gut microbiome in graft fibrosis after pediatric liver transplantation
24. Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats
25. Genotype correlates with the natural history of severe bile salt export pump deficiency
26. Long-Term Neurodevelopmental Outcomes in Children with Biliary Atresia
27. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
28. Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position Paper
29. Recurrence of Disease After Liver Transplantation
30. Unusual Long Absence of Isolated Biliary Atresia in COVID Lockdown: Coincidence or Association?
31. Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis
32. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation
33. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials
34. Treatment strategies for hepatic artery complications after pediatric liver transplantation: A systematic review.
35. Treatment strategies for hepatic artery complications after pediatric liver transplantation: A systematic review
36. Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70−/− Mice with a Human-like Bile Acid Composition
37. Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol
38. P1 Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database
39. Bile Acid Sequestration by Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70-/- Mice with a Human-Like Bile Acid Composition
40. Early Motor Repertoire in Infants with Biliary Atresia: A Nationwide Prospective Cohort Study
41. Intestinal Failure and Aberrant Lipid Metabolism in Patients With DGAT1 Deficiency
42. A Higher Incidence of Isolated Biliary Atresia in Rural Areas: Results from an Epidemiological Study in The Netherlands
43. Quality of Life in Parents of Children With Biliary Atresia
44. Old habits die hard: The age at Kasai portoenterostomy in European infants with biliary atresia.
45. LED-phototherapy does not induce oxidative DNA damage in hyperbilirubinemic Gunn rats
46. Odevixibat therapy following liver transplantation in patients with FIC1-deficient progressive familial intrahepatic cholestasis: a retrospective case series
47. Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome
48. Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database
49. Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group
50. Outcomes in adult patients with progressive familial intrahepatic cholestasis treated with odevixibat: subgroup analysis from the PEDFIC 2 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.